Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 4, 2008, Pages 1160-1167

  Akalin, Enver ^a,d   Dinavahi, Rajani ^a   Friedlander, Rex ^b   Ames, Scott ^a   de Boccardo, Graciela ^a   Sehgal, Vinita ^a   Schröppel, Bernd ^a   Bhaskaran, Madhu ^a,c   Lerner, Susan ^a   Fotino, Marileno ^b   Murphy, Barbara ^a   Bromberg, Jonathan S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ROGOSIN INSTITUTE   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CROSS REACTION; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MORTALITY; PLASMAPHERESIS; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 46249133715     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05321107     Document Type: Article

References (26)

1. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J: Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2: 758-760, 2002
2. Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puliyanda D, Kamil E, Tyan D: Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76: 631-636, 2003
3. Vo AA, Toyoda M, Peng A, Bunnapradist S, Lukovsky M, Jordan SC: Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 6: 2384-2390, 2006
4. Gloor JM, DeGoey SR, Pineda AA, Moore SB, Prieto M, Nyberg SL, Larson TS, Griffin MD, Textor SC, Velosa JA, Schwab TR, Fix LA, Stegall MD: Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 3: 1017-1023, 2003
5. Montgomery RA, Zachary AA: Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatr Transplant 8: 535-542, 2004
6. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70: 887-895, 2000
7. Schweitzer EJ, Wilson JS, Fernandez-Vina M, Fox M, Gutierrez M, Wiland A, Hunter J, Farney A, Philosophe B, Colonna J, Jarrell BE, Bartlett ST: A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 70: 1531-1536, 2000
8. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S: A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6: 346-351, 2006
9. Akalin E, Bromberg JS: Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 66: 359-363, 2005
10. Gebel HM, Bray RA, Nickerson P: Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 3: 1488-1500, 2003
11. Akalin E, Ames S, Sehgal V, Fotino M, Daly L, Murphy B, Bromberg JS: Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 76: 1444-1447, 2003
12. Akalin E, Ames S, Sehgal V, Murphy B, Bromberg JS, Fotino M, Friedlander R: Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 79: 742, 2005
13. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y, et al.: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999
14. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K: Antibody-mediated rejection criteria: An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3: 708-714, 2003
15. Mizutani K, Terasaki P, Hamdani E, Esquenazi V, Rosen A, Miller J, Ozawa M: The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 7: 1027-1031, 2007
16. Akalin E, Pascual M: Sensitization after kidney transplantation. Clin J Am Soc Nephrol 1: 433-440, 2006
17. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D: Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355: 1967-1977, 2006
18. Zand MS: B-cell activity of polyclonal antithymocyte globulins. Transplantation 82: 1387-1395, 2006
19. Shah A, Nadasdy T, Arend L, Brennan J, Leong N, Coppage M, Orloff M, Demme R, Zand MS: Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 77: 1399-1405, 2004
20. Le Bas-Bernardet S, Hourmant M, Valentin N, Paitier C, Giral-Classe M, Curry S, Follea G, Soulillou JP, Bignon JD: Identification of the antibodies involved in B-cell cross-match positivity in renal transplantation. Transplantation 75: 477-482, 2003
21. Bray RA, Nickerson PW, Kerman RH, Gebel HM: Evolution of HLA antibody detection: technology emulating biology. Immunol Res 29: 41-54, 2004
22. Patel AM, Pancoska C, Mulgaonkar S, Weng FL: Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 7: 2371-2377, 2007
23. Gloor JM, Cosio FG, Rea DJ, Wadei HM, Winters JL, Moore SB, DeGoey SR, Lager DJ, Grande JP, Stegall MD: Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 6: 1841-1847, 2006
24. Anglicheau D, Loupy A, Suberbielle C, Zuber J, Patey N, Noel LH, Cavalcanti R, Le Quintrec M, Audat F, Mejean A, Martinez F, Mamzer-Bruneel MF, Thervet E, Legendre C: Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: A pilot study. Am J Transplant 7: 1185-1192, 2007
25. Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchalliska D, Leffell MS: Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 76: 1519-1525, 2003
26. Gloor JM, DeGoey S, Ploeger N, Gebel H, Bray R, Moore SB, Dean PG, Stegall MD: Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 78: 221-227, 2004